THE PROJECT, WITH A TOTAL VALUE OF APPROXIMATELY 7 MILLION EUROS AND AWARDED TO A MULTIDISCIPLINARY CONSORTIUM OF SCIENTIFIC, CLINICAL, AND TECHNOLOGICAL EXCELLENCE, AIMS TO DEVELOP NEW THERAPEUTIC STRATEGIES TO COMBAT ANTIBIOTIC RESISTANCE, ONE OF THE MOST SERIOUS GLOBAL HEALTH EMERGENCIES.

Milan, Monday, November 3, 2025 — Datrix, a company listed on Euronext Growth Milan at the head of the first international ecosystem of vertical Artificial Intelligence software companies, announces its participation in the ARTIBAC project (Artificial Intelligence and Biotechnology Against Multidrug-Resistant Bacteria), funded by Regione Lombardia under the ERDF 2021–2027 – “Collaborate & Innovate” program.

The project, with a total value of approximately 7 million euros and awarded to a multidisciplinary consortium of scientific, clinical, and technological excellence, aims to develop new therapeutic strategies to combat antibiotic resistance, one of the most serious global health emergencies.

According to the WHO, antibiotic resistance causes over one million deaths worldwide every year and represents a growing threat to public health and the sustainability of healthcare systems.

A Lombard alliance between research and technology

The ARTIBAC consortium brings together some of the leading organizations in the Lombard scientific and healthcare system, including:
ASST Fatebenefratelli Sacco (lead partner), University of Pavia, Fondazione Istituto Insubrico di Ricerca per la Vita, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Fondazione Istituto Nazionale Genetica Molecolare – INGM.

Datrix participates as a technological partner, specialized in the development of advanced algorithmic models and Artificial Intelligence systems, with the aim of enhancing predictive analysis capabilities and accelerating the discovery processes of new antibacterial molecules.

AI and HealthTech: a strategy uniting Europe and the territory

The participation in ARTIBAC is part of Datrix’s long-term strategy in the AI & HealthTech field, following two European projects coordinated by the group:

• BETTER, which is developing a distributed healthcare data analysis platform allowing for the secure and decentralized analysis of clinical and genomic data without moving them from the centers that hold them;
• UNICA which extends the European Cancer Imaging Initiative by integrating oncological screening data from across Europe to improve early diagnosis and personalized care through advanced AI models and interoperable infrastructures.

As in these projects, in ARTIBAC Datrix contributes not only to the advancement of academic research but also to the “productization of scientific knowledge”, translating the complexity of machine learning systems into concrete applications to optimize the analysis, development, and validation processes of new treatments.

AI and Biotechnology for faster and more efficient research

Datrix’s contribution focuses on the development of predictive and generative AI models capable of identifying bacterial resistance patterns and supporting the design of new bioactive compounds.
Through the modeling of experimental and clinical data, Datrix technologies will allow for reduced experimentation time and costs, improving the scientific partners’ ability to more quickly and sustainably validate the most promising therapeutic candidates.

“ARTIBAC represents a new example of collaboration between the academic world and applied technology – comments Michele Compare, CTO of the Datrix Group – Our role is to translate the complexity of biotechnological data into intelligent and interoperable models, capable of accelerating research while ensuring security, transparency, and traceability of information.”

The AI of Doing

“The participation in ARTIBAC confirms the consistency of the path Datrix is pursuing with projects like UNICA and BETTER, where Artificial Intelligence becomes an enabler of knowledge and a motor for efficiency for healthcare systems – adds Fabrizio Milano d’Aragona, CEO of the Datrix Group – Our mission is to build a bridge between research and the market, bringing AI from laboratories to clinical practice in a responsible, scalable, and sustainable way. In line with our vision of the AI of doing.”